AZN, why is this stock down, does it have a debt? Does it have a good PS and PA rate, what do other investors see that I do not?

AstraZeneca's stock decline can be attributed to several factors:

1. Clinical Trial Results: AstraZeneca's performance in Q4 was impacted by underwhelming clinical trial results for a new cancer drug. The company presented two underwhelming clinical datasets for the drug, which raised concerns among investors.
2. Withdrawal of COVID Vaccine: AstraZeneca's decision to withdraw its COVID-19 vaccine globally due to the availability of updated vaccines led to a decline in demand for the original vaccine. This contributed to the overall decline in the company's stock price.
3. Market Dynamics: The broader pharmaceutical market is subject to various factors that can impact stock prices, including changes in interest rates, economic conditions, and regulatory developments.

Regarding AstraZeneca's financial health:

1. Debt Level: AstraZeneca has a significant portion of financial liabilities at fixed interest rates, which could be a concern if interest rates rise.
2. Credit Risk: The company's credit risk is assessed by major rating agencies, which can influence investor sentiment.
3. Valuation Metrics: AstraZeneca's price-to-earnings (P/E) ratio is 39.00 as of August 7, 2024, which is considered high, indicating that the stock may be overvalued compared to the earnings it generates. The company's price-to-sales (P/S) ratio is not provided, but it can be inferred that it is also high based on the P/E ratio. The price-to-book (P/B) ratio is not provided either, but it can be estimated based on the company's market capitalization and book value.
4. Investor Sentiment: Other investors may have different perspectives on AstraZeneca's prospects based on factors such as the company's pipeline of drugs, its competitive position in the pharmaceutical market, and the potential for future revenue growth.

In conclusion, AstraZeneca's stock decline is likely a result of a combination of factors, including underwhelming clinical trial results, the withdrawal of the COVID vaccine, and broader market dynamics. The company's financial health, with significant liabilities and high valuation metrics, could also influence investor sentiment.